Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production

Current Opinion in Lipidology

Volumn 23, Issue 3, 2012, Pages 206-212

  Yao, Zemin ^a   Wang, Yuwei ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

apo C III (or apoC3); atherosclerosis; hypertriglyceridemia; insulin resistance; very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN C3; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; DIABETES MELLITUS; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID TRANSPORT; LIPOLYSIS; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; APOLIPOPROTEIN C-III; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; LIVER; TRIGLYCERIDES;

ANIMALIA; MUS;

EID: 84861092483     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328352dc70     Document Type: Review

References (60)

1. Lee HY, Birkenfeld AL, Jornayvaz FR, et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011; 54:1650-1660.
2. Ding Y, Wang Y, Zhu H, et al. Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII. Transgenic Res 2011; 20:867-875.
3. Wei J, Ouyang H, Wang Y, et al. Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII. FEBS J 2012; 279:91-99.
4. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, et al. A mouse model with features of familial combined hyperlipidemia. Science 1997; 275:391-394. (Pubitemid 27051617)
5. Liu H, Labeur C, Xu CF, et al. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr. J Lipid Res 2000; 41:1760-1771.
6. von EA, Holz H, Sandkamp M, et al. Apolipoprotein C-III(Lys58\\Glu). Identification of an apolipoprotein C-III variant in a family with hyper-alphalipoproteinemia. J Clin Invest 1991; 87:1724-1731.
7. Pollin TI, Damcott CM, Shen H,et al.Anull mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322:1702-1705.
8. Maeda N, Li H, Lee D, et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269:23610-23616. (Pubitemid 24293564)
9. Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol 2011; 31:471-473.
10. Sundaram M, Zhong S, Bou KM, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 2010; 51:150-161.
11. Cohn JS, Patterson BW, Uffelman KD, et al. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 2004; 89:3949-3955. (Pubitemid 39071498)
12. Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) 2010; 7:35-51.
13. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351. (Pubitemid 40629054)
14. McFie PJ, Banman SL, Kary S, Stone SJ. Murine diacylglycerol acyl-transferase-2 (DGAT2) can catalyze triacylglycerol synthesis and promote lipid droplet formation independent of its localization to the endoplasmic reticulum. J Biol Chem 2011; 286:28235-28246.
15. Quiroga AD, Lehner R. Liver triacylglycerol lipases. Biochim Biophys Acta 2011 [Epub ahead of print]: http://dx.doi.org/10.1016/j.bbalip.2011.09.007.
16. Tran K, Wang Y, DeLong CJ, et al. The assembly of very low density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by phospholipase A2 antagonists. J Biol Chem 2000; 275:25023-25030. (Pubitemid 30626612)
17. Caviglia JM, Gayet C, Ota T, et al. Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res 2011; 52:1636-1651.
18. Tran K, Sun F, Cui Z, et al. Attenuated secretion of very low density lipoproteins from McA-RH7777 cells treated with eicosapentaenoic acid is associated with impaired utilization of triacylglycerol synthesized via phospholipid remodeling. Biochim Biophys Acta 2006; 1761:463-473. (Pubitemid 43776457)
19. Wang Y, Tran K, Yao Z. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins. J Biol Chem 1999; 274:27793-27800.
20. Griffin BA, Packard CJ. Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 1994; 5:200-206. (Pubitemid 24198816)
21. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886-1892.
22. Tran K, Thorne-Tjomsland G, DeLong CJ, et al. Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells. J Biol Chem 2002; 277:31187-31200. (Pubitemid 34970825)
23. Gordon DA, Wetterau JR, Gregg RE. Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles. Trends Cell Biol 1995; 5:317-321.
24. Liu Y, Manchekar M, Sun Z, et al. Apolipoprotein B-containing lipoprotein assembly in microsomal triglyceride transfer protein-deficient McA-RH7777 cells. J Lipid Res 2010; 51:2253-2264.
25. Shin MJ, Krauss RM. Apolipoprotein CIII bound to apoB-containing lipo-proteins is associated with small, dense LDL independent of plasma trigly-ceride levels in healthy men. Atherosclerosis 2010; 211:337-341.
26. Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 2010; 30:239-245.
27. Zheng C, KhooC, FurtadoJ, Sacks FM. Apolipoprotein C-III and themetabolic basis for hypertriglyceridemia and the dense low-density lipoprotein pheno-type. Circulation 2010; 121:1722-1734.
28. Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011; 124:2065-2072.
29. Holmberg R, Refai E, Hoog A, et al. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci USA 2011; 108:10685-10689.
30. Flood-Nichols SK, Stallings JD, Gotkin JL, et al. Elevated ratio of maternal plasma ApoCIII to ApoCII in preeclampsia. Reprod Sci 2011; 18:493-502.
31. Bernard N, Girouard J, Forest JC, Giguere Y. The combination of ApoCIII, hepatic lipase and hormono sensitive lipase gene polymorphisms suggests an association with susceptibility to gestational hypertension. J Hum Genet 2007; 52:244-254.
32. Sundaram M, Zhong S, Bou KM, et al. Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J Lipid Res 2010; 51:1524-1534.
33. Qin W, Sundaram M, Wang Y, et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J Biol Chem 2011; 286:27769-27780.
34. Gangabadage CS, Zdunek J, Tessari M, et al. Structure and dynamics of human apolipoprotein CIII. J Biol Chem 2008; 283:17416-17427.
35. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995; 270:13470-13475.
36. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005; 115:1323-1332. (Pubitemid 40629052)
37. Claudel T, Inoue Y, Barbier O, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003; 125:544-555. (Pubitemid 36929436)
38. Coste H, Rodriguez JC. Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter. J Biol Chem 2002; 277: 27120-27129. (Pubitemid 34951726)
39. Malmendier CL, Lontie JF, Delcroix C, et al. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989; 77:139-149. (Pubitemid 19136714)
40. Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apo C-III gene by insulin in diabetic mice: correlation with changes in plasma trigly-ceride levels. J Lipid Res 1994; 35:1918-1924. (Pubitemid 24353064)
41. Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004; 114:1493-1503. (Pubitemid 40385579)
42. Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipo-protein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2011; 31:513-519.
43. Brown AM, Wiggins D, Gibbons GF. Glucose phosphorylation is essential for the turnover of neutral lipid and the second stage assembly of triacylglycerol-rich ApoB-containing lipoproteins in primary hepatocyte cultures. Arterioscler Thromb Vasc Biol 1999; 19:321-329. (Pubitemid 29072746)
44. Wu K, Cappel D, Martinez M, Stafford JM. Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipo-protein. Endocrinology 2010; 151:3566-3576.
45. Moon BC, Hernandez-Ono A, Stiles B, et al. Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arterioscler Thromb Vasc Biol 2012; 32:236-246.
46. Phung TL, Roncone A, Jensen KL, et al. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem 1997; 272:30693-30702. (Pubitemid 27527502)
47. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008; 118: 2347-2364. (Pubitemid 351872351)
48. Malmstrom R, Packard CJ, Caslake M, et al. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998; 47:779-787. (Pubitemid 28201808)
49. Chirieac DV, Chirieac LR, Corsetti JP, et al. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab 2000; 279:E1003-E1011.
50. Adiels M, Boren J, Caslake MJ, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25:1697-1703. (Pubitemid 41098943)
51. Gill JM, Brown JC, Bedford D, et al. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 2004; 176:49-56. (Pubitemid 39078644)
52. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008; 7:95-96. (Pubitemid 351168559)
53. Sidossis LS, Mittendorfer B, Walser E, Wolfe RR. Regional disposal of intravenously infused glucose during prolonged hyperglycemia-hyperinsu-linemia. J Nutr Biochem 1999; 10:547-554. (Pubitemid 29440842)
54. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:1225-1236.
55. Sorensen LP, Sondergaard E, Nellemann B, et al. Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men. Diabetes 2011; 60:2257-2264.
56. Sorensen LP, Andersen IR, Sondergaard E, et al. Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men. Diabetes 2011; 60:88-96.
57. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010; 362:1082-1089.
58. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011; 53:467-474.
59. Sentinelli F, Romeo S, Maglio C, et al. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis 2011; 10:93-99.
60. Lee JY, Hong HR, Kang HS. Ethnicity differences in plasma apoC-III levels between African American and Caucasian youths. World J Pediatr 2011; 7:136-142.